The American College of Cardiology and Heart Rhythm Society issued a joint statement soon after CMS published its final rule for the 2023 Medicare Physician Fee Schedule. The groups warned that the final rule could threaten patient access to high-quality care. 

Johnson & Johnson agreed to an upfront payment of $380 per share. Abiomed shareholders can also receive up to an additional $35 per share if certain milestones are met in the years ahead. 

“Once the study begins, it will likely be one of the largest heart pacing clinical trials happening in the world over the next few years," one specialist said. 

The group—which includes engineers, cardiologist, radiologists and other specialists—will attempt to perform a robotic-controlled left atrial appendage occlusion (LAAO) on a patient inside an MRI scanner.

The acquisition includes an initial investment of $35 million and an upfront closing payment of $200 million. By 2029, if the companies reach all targeted regulatory and commercial milestones, the acquisition could cost Cordis up to $1.135 billion in all.

Could wearables help AFib patients take fewer blood-thinning medications and reduce their risk of stroke? The team behind a new seven-year analysis hopes to find out. 

The company plans to integrate the newly acquired microcatheters into its existing robotics platforms.